These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 8028228

  • 21. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
    Cameron NE, Cotter MA, Basso M, Hohman TC.
    Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
    [Abstract] [Full Text] [Related]

  • 22. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N, Koh N, Sakakibara F, Nakamura J, Hamada Y, Wakao T, Hara T, Mori K, Naruse K, Nakashima E, Sakamoto N.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
    [Abstract] [Full Text] [Related]

  • 23. Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC, Jones ML, Gunn DE, Geraci LS, Jones JH, Sawicki DR, Sredy J, Jacot JL, Dicioccio AT, Petrova T, Mitschler A, Podjarny AD.
    J Med Chem; 2005 May 05; 48(9):3141-52. PubMed ID: 15857120
    [Abstract] [Full Text] [Related]

  • 24. Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats.
    Matsumoto T, Ono Y, Kurono M, Kuromiya A, Nakamura K, Bril V.
    J Pharmacol Sci; 2008 Jul 05; 107(3):231-7. PubMed ID: 18635918
    [Abstract] [Full Text] [Related]

  • 25. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-1,3-diones: 2-[(4-bromo-2-fluorophenyl)methyl]-6- fluorospiro[isoquinoline-4(1H),3'-pyrrolidine]-1,2',3,5'(2H)-tetrone and congeners. 1.
    Malamas MS, Hohman TC, Millen J.
    J Med Chem; 1994 Jun 24; 37(13):2043-58. PubMed ID: 8027986
    [Abstract] [Full Text] [Related]

  • 26. The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats.
    Yamamoto T, Takakura S, Kawamura I, Seki J, Goto T.
    Life Sci; 2001 Feb 09; 68(12):1439-48. PubMed ID: 11388695
    [Abstract] [Full Text] [Related]

  • 27. Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
    Kato K, Nakayama K, Ohta M, Murakami N, Murakami K, Mizota M, Miwa I, Okuda J.
    Eur J Pharmacol; 1991 Feb 07; 193(2):185-91. PubMed ID: 1828768
    [Abstract] [Full Text] [Related]

  • 28. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.
    Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, Siegel TW, Singleton DH.
    J Med Chem; 1991 Jan 07; 34(1):108-22. PubMed ID: 1899452
    [Abstract] [Full Text] [Related]

  • 29. Increased resistance to hypoxic conduction block in sciatic nerves of diabetic rats: effects of extracellular glucose concentration and of aldose reductase inhibition.
    Carrington AL, Ettlinger CB, Tomlinson DR.
    J Diabetes Complications; 1994 Jan 07; 8(1):33-9. PubMed ID: 8167385
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats.
    Simard-Duquesne N, Greselin E, Dubuc J, Dvornik D.
    Metabolism; 1985 Oct 07; 34(10):885-92. PubMed ID: 3930915
    [Abstract] [Full Text] [Related]

  • 38. Polyol pathway hyperactivity is closely related to carnitine deficiency in the pathogenesis of diabetic neuropathy of streptozotocin-diabetic rats.
    Nakamura J, Koh N, Sakakibara F, Hamada Y, Hara T, Sasaki H, Chaya S, Komori T, Nakashima E, Naruse K, Kato K, Takeuchi N, Kasuya Y, Hotta N.
    J Pharmacol Exp Ther; 1998 Dec 07; 287(3):897-902. PubMed ID: 9864270
    [Abstract] [Full Text] [Related]

  • 39. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR, Moriarty RJ, Mayer JH.
    Diabetes; 1984 May 07; 33(5):470-6. PubMed ID: 6202576
    [Abstract] [Full Text] [Related]

  • 40. Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Lim SS, Jung SH, Ji J, Shin KH, Keum SR.
    J Pharm Pharmacol; 2001 May 07; 53(5):653-68. PubMed ID: 11370705
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.